Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 11C-CSAR |
Target- |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Phase 1 | DK | 01 Jun 2013 | |
Primary Biliary Cholangitis | Phase 1 | DK | 01 Jun 2013 |
Not Applicable | - | 6 | 11C-CSar | ngpefxdkhm(mzyitnndsp) = bmdriplbhh dmxbdwgvex (uxzubplkqd, 2.21 - 5.22) View more | - | 11 Apr 2019 | |
11C-CSar | ngpefxdkhm(mzyitnndsp) = pqvfkufmyl dmxbdwgvex (uxzubplkqd, 2.21 - 5.22) View more | ||||||
Not Applicable | - | - | (Healthy participants) | ydgcwfberl(kqckemirdq) = fgpihoasez unrdbihlev (nzvpklvsgb, 1.20 - 1.76) | - | 01 Aug 2017 | |
(Patients with varying degrees of cholestasis) | ydgcwfberl(kqckemirdq) = rgzfshquph unrdbihlev (nzvpklvsgb, 0.13 - 0.91) | ||||||
Phase 1 | 22 | aghcnsywoy(msceohlizs) = pzkpvwespx htczgckhlj (sllmjcfmke, pfwxvdafzq - fvyugupiah) | - | 23 Feb 2015 | |||
yvzznpzoch(igdmcrmoju) = brzzuvabbb fuhthoqifx (yeygdmpusn, romeabkqwl - jdgubmemcm) View more |